



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

LRRK2-IN-13

Cat. No.:	HY-161571
CAS No.:	3032733-17-5
Molecular Formula:	C ₁₉ H ₁₉ ClN ₈ O ₂
Molecular Weight:	426.86
Target:	LRRK2
Pathway:	Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LRRK2-IN-13 (Compound 13) is an inhibitor of LRRK2 (IC ₅₀ =0.57 nM). LRRK2-IN-13 has brain penetrating properties ^[1] .
In Vitro	LRRK2-IN-13 inhibits the effects of LRRK2 is IC ₅₀ =0.57 nM (WT), 0.22 nM (LRRK2 G2019S), 0.33 nM (LRRK2 WT ADPGlo), respectively ^[1] . LRRK2-IN-13 (0.05 μM; 1-120 min) has an intrinsic hepatocyte clearance of 1.88 (L/h/kg) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jensen, T, et al. Preparation of substituted 2,4,12,13-tetrahydro-11H-5,7-(azeno-metheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine derivatives as leucine-rich repeat kinase 2 (LRRK2) inhibitors. World Intellectual Property Organization, WO2024056775 A1 2024-03-21

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA